Skip to main content
main-content

The independent medical news service

13-05-2021 | Oncology | News | Article

Real-world pneumonitis rates with pembrolizumab–chemotherapy exceed clinical trial data

A Japanese real-world study has found higher rates of pneumonitis with first-line pembrolizumab plus chemotherapy among patients with advanced nonsquamous non-small-cell lung cancer than previously reported in clinical trials.

07-05-2021 | Oncology | News | Article

Dacomitinib has ‘limited benefit’ after first-line osimertinib

Second-line dacomitinib treatment is associated with a low objective response rate among patients with EGFR-mutated non-small-cell lung cancer who progress on first-line osimertinib, report US researchers.

04-05-2021 | Oncology | News | Article

KEYNOTE-189 final analysis confirms pembrolizumab nonsquamous NSCLC benefits

The addition of pembrolizumab to pemetrexed–paclitaxel chemotherapy provides durable survival advantages for treatment-naïve patients with metastatic, nonsquamous non-small-cell lung cancer, the final protocol-specified analysis of KEYNOTE-189 has confirmed.

26-04-2021 | Oncology | News | Article

EMA recommends extending osimertinib indication

Find out more about this decision here

22-04-2021 | Oncology | News | Article

Limited evidence to link antihypertensive use to cancer

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

19-04-2021 | Oncology | News | Article

Chemoimmunotherapy may be preferable for KRAS wild-type NSCLC

Chemoimmunotherapy may be a better option than immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer patients with high PD-L1 expression and no KRAS mutations, indicate findings.